Harga Akedo (AKE) melonjak 75,06% menjadi $0,0280 tanpa adanya berita atau peristiwa spesifik yang menjelaskan kenaikan dramatis ini, memicu spekulasi di kalangan investor. Di sisi lain, Pi Network (PI) turun 12,21% menjadi $0,0862 di tengah skeptisisme tentang proyek tersebut. Volatilitas ini menyoroti sifat pasar kripto yang tidak dapat diprediksi, di mana keuntungan dan kerugian besar dapat terjadi secara bersamaan, menunjukkan pentingnya kehati-hatian bagi investor.
For readers following Akedo and Pi Network, here is Pluang's market snapshot as of Sep 16, 2026 08:51 WIB: of 50 priced major cryptocurrencies tradable on Pluang, 4 rose and 45 fell today. EOS (EOS.IO) saw a 1-day change of +8.13%, while EGLD (MultiversX) declined by -8.46%. ZIL (Zilliqa) had a typical hold time on Pluang of 132 Days, with 96% buy activity.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
